Press release
KemPharm Reports Third Quarter 2021 Financial Results and Corporate Updates
Lead Independent Director Richard W. Pascoe Named Executive Chairman Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today,
About this update from Zevra Therapeutics, Inc.
[{"type":"text","content":"Lead Independent Director Richard W. Pascoe Named Executive Chairman Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today, November 10, 2021, 4:30 p.m. ET Corporate and Regulatory Highlights Appointment of Richard W. Pascoe as Executive Chairman; Mr. Pascoe to focus on executing the Company’s strategic growth plansUplisted to The Nasdaq Global Select MarketResearch involving AZSTARYS® and serdexmethylphenidate featured in poster presentations at multiple medical conferences during ADHD Awareness Month (October) Data presented during the 2021 Virtual International Conference on ADHD affirmed AZSTARYS’ 30-minute onset of action and 13-hour duration of effect Appointed Tamara A. Seymour to Board of DirectorsU.S. commercial launch of AZSTARYS initiated on July 21, 2021 Financial Highlights Q3 2021 net loss of $0.05 per basic shareReported Q3 2021 revenue of $2.0 millionTotal cash and cash equivalents was $131.5 million at September 30, 2021 CELEBRATION, Fla., Nov. 10, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today reported its financial results for the third quarter ended September 30, 2021. In addition, the Company announced that Richard W. Pascoe, lead independent director on the Board of Directors, has been named Executive Chairman to support execution of the Company’s strategic growth objectives to expand its pipeline and commercialization capabilities. Travis C. Mickle, Ph.D., remains the Company’s President and Chief Executive Officer, and as a member of the Board of Directors. “I am delighted to partner with Rich in his new role as Executive Chairman as we build upon our successful track record of clinical development and U.S. regulatory approvals to create an innovative biopharmaceutical company with an expanded pipeline and commercial capabilities,” stated Dr. Mickle. “Rich and I have built a strong working relationship since he joined our Board in 2014, and I am proud of our many accomplishments at KemPharm to date. Working together to expand the Company’s growth opportunities will be exciting as together we pursue our shared goal to increase shareholder value.” “I am excited for the opportunity to continue my service to KemPharm as its Executive Chairman and to partner with Trav...